The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(3R)-3-(methoxymethyl)-7-[5-methyl-2[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-2-[(6-methyl-2-pyridyl)methyl]-3,4 dihydropyrrolo[1,2-a]pyrazin-1-one ID: ALA4551714
PubChem CID: 122604308
Max Phase: Preclinical
Molecular Formula: C25H28N8O2
Molecular Weight: 472.55
Molecule Type: Unknown
Associated Items:
Names and Identifiers Canonical SMILES: COC[C@H]1Cn2cc(-c3nc(Nc4ccnn4C)ncc3C)cc2C(=O)N1Cc1cccc(C)n1
Standard InChI: InChI=1S/C25H28N8O2/c1-16-11-26-25(29-22-8-9-27-31(22)3)30-23(16)18-10-21-24(34)33(13-19-7-5-6-17(2)28-19)20(15-35-4)14-32(21)12-18/h5-12,20H,13-15H2,1-4H3,(H,26,29,30)/t20-/m1/s1
Standard InChI Key: CZSJKHCGJOLSDZ-HXUWFJFHSA-N
Molfile:
RDKit 2D
35 39 0 0 0 0 0 0 0 0999 V2000
13.5111 -22.8772 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.5100 -23.7009 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.2222 -24.1139 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
14.9359 -23.7004 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.9331 -22.8736 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
14.2204 -22.4683 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.6484 -24.1120 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
16.3596 -23.6982 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.1072 -24.0323 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
17.6530 -23.4201 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
17.2433 -22.7088 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.4401 -22.8801 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.2781 -24.8356 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.7992 -22.4688 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.2184 -21.6471 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.8822 -21.1606 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.5518 -21.1646 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.8019 -20.3825 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.6235 -20.3806 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
15.0324 -19.6715 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.6202 -18.9598 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.7986 -18.9617 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
13.3892 -19.6753 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.5679 -19.6784 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
13.3890 -18.2545 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.7967 -17.5421 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.6177 -17.5432 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
15.0294 -16.8316 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.6157 -16.1194 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.7901 -16.1231 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.3862 -16.8352 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.8466 -16.8309 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.0274 -18.2513 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.8446 -18.2498 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
16.2519 -17.5413 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 4 2 0
4 5 1 0
5 6 2 0
6 1 1 0
4 7 1 0
7 8 1 0
8 9 1 0
9 10 1 0
10 11 2 0
11 12 1 0
12 8 2 0
9 13 1 0
1 14 1 0
15 16 2 0
16 19 1 0
18 17 2 0
17 15 1 0
6 15 1 0
18 19 1 0
18 23 1 0
19 20 1 0
20 21 1 0
21 22 1 0
22 23 1 0
23 24 2 0
22 25 1 0
25 26 1 0
26 27 2 0
27 28 1 0
28 29 2 0
29 30 1 0
30 31 2 0
31 26 1 0
28 32 1 0
21 33 1 1
33 34 1 0
34 35 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 472.55Molecular Weight (Monoisotopic): 472.2335AlogP: 3.11#Rotatable Bonds: 7Polar Surface Area: 102.99Molecular Species: NEUTRALHBA: 9HBD: 1#RO5 Violations: ┄HBA (Lipinski): 10HBD (Lipinski): 1#RO5 Violations (Lipinski): ┄CX Acidic pKa: 12.78CX Basic pKa: 4.85CX LogP: 2.31CX LogD: 2.31Aromatic Rings: 4Heavy Atoms: 35QED Weighted: 0.44Np Likeness Score: -1.39
References 1. Ward RA, Anderton MJ, Bethel P, Breed J, Cook C, Davies EJ, Dobson A, Dong Z, Fairley G, Farrington P, Feron L, Flemington V, Gibbons FD, Graham MA, Greenwood R, Hanson L, Hopcroft P, Howells R, Hudson J, James M, Jones CD, Jones CR, Li Y, Lamont S, Lewis R, Lindsay N, McCabe J, McGuire T, Rawlins P, Roberts K, Sandin L, Simpson I, Swallow S, Tang J, Tomkinson G, Tonge M, Wang Z, Zhai B.. (2019) Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC)., 62 (24): [PMID:31710489 ] [10.1021/acs.jmedchem.9b01295 ]